ENDO 2024
Bone density changes correlate with fracture risk reduction, regardless of mechanism of action
www.high5endocrinology.tv | Meeting coverage | ENDO 2024
Calcium & bone
FNIH-ASBMR-SABRE Project
ENDO 2024
Bone density changes correlate with fracture risk…
ENDO 2024
Haematopoiesis & bone - a new connection
ENDO 2024
No fear of osteoporosis with SGLT2 inhibitors
Orbit
ENDO 2024
Sclerostin antibody therapy for osteogenesis imperfecta
VITAL
ENDO 2024
Low Vitamin K and high Vitamin D levels increase risk…
ENDO 2024
Social isolation induces bone loss
ENDO 2024
Bone turnover markers can predict the increase in bone…
ENDO 2024
Bisphosphonate drug holidays - when to start and when…
ENDO 2024
No difference between denosumab and zoledronic acid on…
ENDO 2024
A model for the strength of virtual screws in the spine
ENDO 2024
Hypoparathyroidism - best practice recommendations
ENDO 2024
Haematopoiesis & bone - a new connection
ENDO 2024
Bisphosphonate drug holidays - when to start and when to stop?
ENDO 2024
No difference between denosumab and zoledronic acid on mortality in diabetes
ENDO 2024
Hypoparathyroidism - best practice recommendations
Diabetes & obesity
ENDO 2024
Fatty liver
ENDO 2024
25 years of CGM - advances in research, technology and…
ENDO 2024
Retatrutide for the treatment of obesity
ENDO 2024
Obesity programming before and during pregnancy
ENDO 2024
There is hope on prevention of type 1 diabetes
ENDO 2024
Obesity debate: medical vs. surgical - injection vs.…
ENDO 2024
Opening plenary - diabetes at the heart of…
ENDO 2024
Fatty liver
Rinella et al. J Hepatol. 2023;79(6):1542-1556.
Loomba et al. N Engl J Med. 2024
Sanyal et al. N Engl J Med. 2024 Jun 7. Epub ahead of print. doi: 10.1056/NEJMoa2401755.
Cusi. N Engl J Med. 2024 Feb 8;390(6):559-561.
ENDO 2024
25 years of CGM - advances in research, technology and the opportunity for patient involvement through active prevention
Bergenstal. Diabetes Spectr. 2023;36(4):284-286.
Bergenstal. Diabetes Spectr. 2023;36(4):327-336.
ENDO 2024
Retatrutide for the treatment of obesity
Jastreboff et al. N Engl J Med. 2023;389(6):514-526.
Rosenstock et al. Lancet. 2023;402(10401):529-544.
ENDO 2024
Obesity programming before and during pregnancy
ENDO 2024
There is hope on prevention of type 1 diabetes
Ramos et al. N Engl J Med. 2023;389(23):2151-2161.
Herold et al. N Engl J Med. 2019;381(7):603-613.
Waibel et al. N Engl J Med. 2023;389(23):2140-2150.
TArgeting Type 1 Diabetes Using POLyamines (TADPOL)
ENDO 2024
Obesity debate: medical vs. surgical - injection vs. knife
ENDO 2024
Opening plenary - diabetes at the heart of endocrinology
Ndumele et al. Circulation. 2023;148(20):1636-1664.
Ndumele et al. Circulation. 2024;149(13):e1023
Global Cardiovascular Risk Consortium et al. N Engl J Med. 2023;389(14):1273-1285.
Neuroendocrinology & pituitary
ENDO 2024
Arthropathy in acromegaly
ENDO 2024
Vasopressin deficiency & first guideline on pituitary…
ENDO 2024
Prolactinoma and pituitary apoplexy management-…
ENDO 2024
Adaptation of medical aftercare to tumor biology
ENDO 2024
Arthropathy in acromegaly
ENDO 2024
Vasopressin deficiency & first guideline on pituitary adenoma in children
Hoshino et al. J Clin Endocrinol Metab. 2024;109(3):e983-e996.
Cooper et al. J Clin Endocrinol Metab. 2023;108(8):e623-e633.
Korbonits et al. Nat Rev Endocrinol. 2024;20(5):278-289.
Korbonits et al. Nat Rev Endocrinol. 2024;20(5):290-309.
ENDO 2024
Prolactinoma and pituitary apoplexy management- considerations between endocrinologist and neurosurgeon
Chen et al. J Clin Endocrinol Metab. 2024;109(6):1433-1442.
Petersenn. Nat Rev Endocrinol. 2023;19(12):722-740.
Mamelak et al. J Clin Endocrinol Metab. 2024;109(2):e711-e725.
ENDO 2024
Adaptation of medical aftercare to tumor biology
SAT-082
Hamblin et al. Eur J Endocrinol. 2023;189(1):87-95.
Thyroid
ENDO 2024
Non-coding short tandem repeats as a new molecular…
ENDO 2024
Importance of molecular diagnostics with a view to the…
ENDO 2024
Significance of the local control of thyroid hormone…
ENDO 2024
Thyroid cancer - basics for a better clinical…
ENDO 2024
Non-coding short tandem repeats as a new molecular mechanism of TSH resistance & thyroid pathology
OR29-03
Grasberger, et al. Nat Genet. 2024;56(5):877-888.
ENDO 2024
Importance of molecular diagnostics with a view to the new ATA 2024 guidelines
ENDO 2024
Significance of the local control of thyroid hormone action
Cho et al. Commun Biol. 2023 Dec 11;6(1):1253.
Aramaki et al. Proc Natl Acad Sci U S A. 2022 Dec 6;119(49):e2209884119.
Marcelino et al. J Endocr Soc. 2020 Sep 22;4(11):bvaa136.
Salas-Lucia et al. JCI Insight. 2024 Feb 20;9(7):e174645.
Batistuzzo et al. Endocrinology. 2023 Nov 2;164(12):bqad155.
Salas-Lucia et al. Elife. 2023 May 19;12:e82683.
ENDO 2024
Thyroid cancer - basics for a better clinical understanding
Landa, Cabanillas. Nat Rev Endocrinol. 2024 Feb;20(2):93-110.
Landa et al. Mol Cancer Res. 2023 Nov 1;21(11):1163-1175.
Fagin, Krishnamoorthy, Landa. Nat Rev Cancer. 2023 Sep;23(9):631-650.
Weiterführende Literatur: Lu et al. J Clin Invest. 2023 Jun 1;133(11):e169653.
Cross-cutting highlights
ENDO 2024
Machine learning for endocrine tumours
ENDO 2024
New vitamin D guideline - for prevention
ENDO 2024
Guideline on glucocorticoid-induced adrenal…
ENDO 2024
Plenary II - AI in healthcare and research
ENDO 2024
New aspects of postmenopausal hormone therapy
ENDO 2024
Machine learning for endocrine tumours
Thomasian, Kamel, Bai. Nat Rev Endocrinol. 2022 Feb;18(2):81-95.
Ku et al. Endocrinol Metab (Seoul). 2021 Oct;36(5):1131-1141.
Khan et al. Endocr Rev. 2023 Sep 15;44(5):947-959.
Chari et al. World Neurosurg. 2021 Feb;146:140-147.
Pozdeyev et al. J Clin Endocrinol Metab. 2024 Jan 18;109(2):402-412.
ENDO 2024
New vitamin D guideline - for prevention
ENDO 2024
Guideline on glucocorticoid-induced adrenal insufficiency
ENDO 2024
Plenary II - AI in healthcare and research
Assié, Allassonnière. J Clin Endocrinol Metab. 2024;109(6):e1462-e1467.
McMahon. J Clin Endocrinol Metab. 2024;109(6):e1468-e1471.
ENDO 2024
New aspects of postmenopausal hormone therapy
